A detailed history of Squarepoint Ops LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 112,667 shares of STOK stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
112,667
Previous 15,042 649.02%
Holding current value
$1.28 Million
Previous $203,000 581.77%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.24 - $15.92 $1.19 Million - $1.55 Million
97,625 Added 649.02%
112,667 $1.38 Million
Q2 2024

Aug 14, 2024

SELL
$11.03 - $17.52 $397,686 - $631,683
-36,055 Reduced 70.56%
15,042 $203,000
Q1 2024

May 15, 2024

BUY
$4.12 - $14.17 $131,844 - $453,454
32,001 Added 167.58%
51,097 $689,000
Q4 2023

Feb 14, 2024

BUY
$3.37 - $5.4 $64,353 - $103,118
19,096 New
19,096 $100,000
Q1 2023

May 15, 2023

BUY
$7.65 - $10.38 $136,560 - $185,293
17,851 New
17,851 $148,000
Q3 2021

Nov 15, 2021

SELL
$23.65 - $34.44 $153,606 - $223,687
-6,495 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$30.53 - $41.09 $128,745 - $173,276
-4,217 Reduced 39.37%
6,495 $219,000
Q1 2021

May 17, 2021

BUY
$36.08 - $69.81 $386,488 - $747,804
10,712 New
10,712 $416,000
Q4 2020

Feb 16, 2021

SELL
$33.62 - $61.93 $364,339 - $671,135
-10,837 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$22.23 - $37.48 $240,906 - $406,170
10,837 New
10,837 $363,000
Q1 2020

May 15, 2020

SELL
$16.8 - $34.15 $340,804 - $692,766
-20,286 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$20.01 - $30.79 $28,274 - $43,506
-1,413 Reduced 6.51%
20,286 $574,000
Q3 2019

Nov 14, 2019

BUY
$20.53 - $37.72 $445,480 - $818,486
21,699 New
21,699 $466,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $446M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.